Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03428802 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

A Phase 2 study of Metastatic Malignant Solid Neoplasm and Recurrent Ovarian Carcinoma, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT03428802 is a Phase 2 study of Metastatic Malignant Solid Neoplasm and Recurrent Ovarian Carcinoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 40 participants, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03428802, a Phase 2 study of Metastatic Malignant Solid Neoplasm and Recurrent Ovarian Carcinoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Metastatic Malignant Solid Neoplasm Recurrent Ovarian Carcinoma Recurrent Malignant Solid Neoplasm Stage III Breast Cancer AJCC v7 Stage III Ovarian Cancer AJCC v8 BRCA1 Gene Mutation BRCA2 Gene Mutation POLD1 Gene Mutation POLE Gene Mutation Locally Advanced Solid Neoplasm

Interventions

  • BIOLOGICAL Pembrolizumab
  • OTHER Laboratory Biomarker Analysis

Study Locations (2)

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-03-08
Est. Completion 2023-10-02
Phase Phase 2

Sponsor

Rutgers, The State University of New Jersey

413 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03428802

The ClinicalTrials.gov registry entry for NCT03428802 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (81% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT03428802 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT03428802 about?

NCT03428802 is a clinical study titled "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability". This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow...

What is the current status of trial NCT03428802?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-03-08. Estimated completion is 2023-10-02.

What conditions does trial NCT03428802 study?

This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Malignant Solid Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8.

What interventions are being tested in trial NCT03428802?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT03428802?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03428802 being conducted?

This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Malignant Solid Neoplasm

All registered trials for this condition

Recurrent Ovarian Carcinoma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.